Compare VHC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | BDSX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Precision Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 122.0M |
| IPO Year | 2008 | 2020 |
| Metric | VHC | BDSX |
|---|---|---|
| Price | $14.63 | $15.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 10.0K | ★ 127.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,000.00 | ★ $88,499,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | N/A | $26.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $6.60 | $0.25 |
| 52 Week High | $29.00 | $17.40 |
| Indicator | VHC | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 73.20 |
| Support Level | $12.53 | $6.33 |
| Resistance Level | $21.31 | N/A |
| Average True Range (ATR) | 1.64 | 1.71 |
| MACD | -0.26 | 0.29 |
| Stochastic Oscillator | 14.66 | 74.31 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.